Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02416128 |
Recruitment Status :
Withdrawn
(No participants enrolled)
First Posted : April 14, 2015
Last Update Posted : August 30, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The investigators plan to use an herbal eye drop, Euphrasia, aka Eyebright, for post-operative inflammation for Peripheral Laser Iridotomy for the treatment of narrow angle glaucoma. A peripheral Laser Iridotomy is a simple laser procedure with few complications if the patient follows the post-operative instructions. In this procedure, a blue-green Argon laser is used to create an orifice in the iris to open the angle by allowing the aqueous from behind the iris to enter the anterior chamber. Rarely the procedure needs to be repeated. The main complications from this surgery are postoperative inflammation, bleeding, and postoperative pressure spikes.
The investigators will be using Weleda's Euphrasia D3 eye drops. The investigators plan to do a double blinded randomized control trial to objectively measure ocular inflammation in the same process that was used for the steroid eye drops that are currently out on the market. Some patients will be receiving steroids, prednisolone acetate, others, the herbal eye drop.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Iritis | Drug: Euphrasia Drug: Prednisolone acetate | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology |
Estimated Study Start Date : | April 30, 2015 |
Actual Primary Completion Date : | March 25, 2016 |
Actual Study Completion Date : | March 25, 2016 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Iritis prevention after LPI: prednisolone
To use prednisolone acetate after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 2.
|
Drug: Prednisolone acetate
1 drop in the treated eye QID X 10 days
Other Name: Pred Forte |
Experimental: Iritis prevention after LPI: euphrasia
To use euphrasia after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 1.
|
Drug: Euphrasia
1 drop in the treated eye QID X 10 days
Other Name: Eyebright |
- Anti-inflammatory [ Time Frame: 15 days post laser ]Quantitative amount of cell in the anterior chamber (0-5) Measurement of cell in the anterior chamber: 0 = 0 cells; 1 = 1 to 10 cells; 2 = 11 to 20 cells; 3 = 21 to 50 cells; and 4 = >50 cells (based on studies used to assess efficacy of other topical steroids)
- Side effects [ Time Frame: 15 days post laser ]Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Pain prevention [ Time Frame: 15 days post laser ]Pain assessment: Yes or No pain Pain will be measured as quantitative (Yes/No) (based on studies used to assess efficacy of other topical steroids)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients undergoing Peripheral Laser Iridotomy
Exclusion Criteria:
- Patients who have had an allergic reaction to Euphrasia (this will be asked to the patient at time of )
- Patients who have had an adverse reaction to steroids (obtained by chart review to determine safety of drop use)
- Patients who have inflammation before the LPI (Noted by seeing cell in the anterior chamber)
- Patients who had any complications during their cataract surgery (obtained by chart review to determine safety of procedure)
- Patients in whom more than 1500mW of energy was used during the Peripheral Laser Iridotomy
- Patients in whom the laser was used more than 130 times during the Peripheral Laser Iridotomy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02416128
Principal Investigator: | Austin Bach, DO | Larkin Community Hospital/Nova Southeastern University |
Publications of Results:
Responsible Party: | Larkin Community Hospital |
ClinicalTrials.gov Identifier: | NCT02416128 |
Other Study ID Numbers: |
LCH-4-012015 |
First Posted: | April 14, 2015 Key Record Dates |
Last Update Posted: | August 30, 2019 |
Last Verified: | August 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Study was terminated |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Iritis Iris Diseases Uveal Diseases Eye Diseases Uveitis, Anterior Panuveitis Uveitis Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate |
Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents |